GlobeNewswire·Oct 7, 2025, 7:00 AM ET

Jade Biosciences Announces $135 Million Private Placement

Jade Biosciences, Inc. entered a securities purchase agreement for a PIPE financing expected to generate approximately $135 million in gross proceeds before fees & expenses.
The investment included participation from new & existing investors such as Janus Henderson Investors, Fairmount, RA Capital Management, Marshall Wace, Aberdeen Investments, Great Point Partners, Venrock Healthcare Capital Partners, Samsara BioCapital, & Avidity Partners.
The transaction involves selling 13,368,164 shares of common stock at $9.14 per share & pre-funded warrants to purchase 1,402,092 shares at $9.1399 per warrant.
Post-transaction, approximately 67.4 million shares of common stock & common stock equivalents will be issued & outstanding.
The financing is expected to close on or about October 8, 2025, subject to customary closing conditions.
Net proceeds will fund research & development, general corporate expenses, & working capital needs, with cash expected to support operations into the first half of 2028.
Jefferies, TD Cowen, Stifel, & Wedbush & Co. served as placement agents for the transaction.
Jade agreed to file a registration statement with the SEC to register the resale of securities sold in the PIPE financing under a concurrent registration rights agreement.
Jade is a clinical-stage biotechnology company developing therapies for autoimmune diseases, with its lead candidate JADE101 currently in a Phase 1 trial for IgAN.